Deal Talk: Sycamore Partners to Acquire Walgreens Boots Alliance for $10B

Good morning. Welcome to The Deal Talk where each week we break down a recent M&A deal.

Today we’re going to dive into Sycamore Partners’ acquisition of Walgreens Boots Alliance (WBA) for approximately $10 billion.

First time reading? Subscribe here

DEEP DIVE
Sycamore Partners to Acquire Walgreens Boots Alliance for $10B

Sycamore Partners, a New York-based private equity firm specializing in retail and consumer investments, has signed a definitive agreement to acquire Walgreens Boots Alliance (WBA) for approximately $10 billion. Walgreens, founded in 1901, is one of the largest pharmacy chains in the U.S., operating thousands of stores across the country.

Despite its historical dominance, Walgreens has struggled with declining profits and increased competition from major players like Amazon and CVS Health, contributing to a fall in market capitalization from over $100 billion in 2015 to approximately $9.3 billion in 2025. The transaction is expected to close by the end of 2025, pending regulatory approval.

Sycamore Partners has a track record of acquiring and restructuring distressed retail businesses, with a portfolio that includes brands such as Staples, Talbots, and Nine West. The firm's investment approach focuses on operational improvement and long-term growth strategies, often taking companies private to facilitate restructuring outside the public eye.

Strategic Rationale

The acquisition aligns with Sycamore's strategy to invest in underperforming retail businesses with turnaround potential.

For Walgreens, going private offers a reprieve from the pressures of public markets and an opportunity to refocus on its core pharmacy operations. Sycamore's operational expertise and capital resources position Walgreens for a comprehensive restructuring effort aimed at restoring profitability. The partnership could also help Walgreens adapt to shifting consumer behaviors and evolving healthcare demands.

For Sycamore, the deal represents a significant expansion into the healthcare retail space, offering the potential to leverage Walgreens' extensive store network and customer base. Walgreens' leadership team is expected to remain intact post-acquisition, preserving institutional knowledge while facilitating the transition to private ownership.

Financial Impact & Valuation Premium

Sycamore's $10 billion offer equates to $11.45 per share, representing an 8% premium over Walgreens' closing price of $10.60 on the day of the announcement. Additionally, shareholders may receive up to $3 per share from the future monetization of Walgreens' primary-care assets, which could increase the total equity value of the deal to nearly $10 billion. Including debt, the total transaction value reaches approximately $23.7 billion.

The valuation suggests an EV/EBITDA multiple within the range of 9x to 12x, consistent with other private equity deals in the retail and healthcare sectors. This premium reflects investor confidence in Sycamore's ability to reverse Walgreens' declining performance and unlock value through operational efficiencies.

Deal Structure & Financial Advisors

• Transaction Type: Leveraged buyout

• Financing: Debt financing secured from a consortium of banks and private-credit firms

• Ownership: Sycamore will acquire a controlling stake in Walgreens, with Stefano Pessina, the company's largest shareholder, rolling his 17% stake into the new private structure

• Investment Strategy: Long-term, focusing on operational improvements and a strategic realignment toward core pharmacy services

• Financial Advisors for Walgreens: Centerview Partners (financial) and Kirkland & Ellis (legal)

• Financial Advisors for Sycamore Partners: UBS Investment Bank (financial) and Davis Polk & Wardwell (legal)

Opinion & Outlook

What Could Go Right?

• Operational Expertise: Sycamore's track record in retail turnarounds could drive significant improvements in Walgreens' operational efficiency and cost structure.

• Strategic Flexibility: As a private entity, Walgreens can pursue long-term investments and restructuring initiatives without the pressures of public-market scrutiny.

• Market Position: Walgreens' vast store network and established brand provide a strong foundation for growth and potential synergies with other Sycamore-owned assets.

What Could Go Wrong?

• Execution Risk: Large-scale operational changes are complex and may disrupt Walgreens' daily operations if not managed carefully.

• Competitive Pressures: Walgreens faces intense competition from Amazon, CVS Health, and emerging digital health platforms, which could limit the effectiveness of Sycamore's turnaround strategy.

Conclusion

Sycamore Partners' acquisition of Walgreens Boots Alliance marks a major shift in the retail pharmacy landscape. For Walgreens, the move to private ownership provides a pathway to restructure and refocus its business model without public market pressures. For Sycamore, the deal expands its portfolio into a critical sector with substantial growth potential.

As private equity continues to play a prominent role in reshaping the retail and healthcare industries, this transaction underscores the attractiveness of legacy brands with strong infrastructure but struggling financial performance. If successful, the deal could set a precedent for further private equity investments in the healthcare retail space.

THAT’S A WRAP
Here’s How We Can Help

Interview Prep: Have an interview coming up? Head to HirePrep’s website to try out their high finance interview prep platform for free!

Jobs: we’re tracking all open jobs for the classes of 2025 - 2028. Our list is updated daily. Check them out here

Mentorship: if you’re interested in 1:1 career mentorship, click here to book a discovery call.

See you next week,

The Deal Talk Team